NASDAQ: $RIGL
Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and commercial objectives.
Mr. Miller currently serves as the Chief Financial Officer of Vertex Pharmaceuticals Incorporated, a position he has held since 2009. His extensive tenure at Vertex has been instrumental in guiding the company through periods of substantial growth, significant regulatory milestones, and the successful commercialization of several transformative medicines. Before his role as CFO, Mr. Miller held various leadership positions within Vertex, demonstrating a comprehensive understanding of corporate finance, investor relations, and operational management within the life sciences industry.
Commenting on the appointment, Elhanan Harel, Chairman of Rigel’s Board of Directors, expressed enthusiasm for the new addition. “We are extremely pleased to welcome Michael to the Rigel Board. His proven track record in financial stewardship and strategic leadership at a major, innovative biotechnology company like Vertex will be invaluable to Rigel as we execute on our near-term priorities and focus on maximizing the potential of our portfolio,” Harel stated.
In connection with his appointment, Mr. Miller will serve on the Board’s Audit Committee. Rigel noted that the Board now comprises seven members, reflecting a commitment to robust governance and diverse expertise. Rigel Pharmaceuticals is dedicated to discovering, developing, and commercializing innovative medicines that address unmet medical needs in hematology, oncology, and other specialized therapeutic areas.
The addition of an experienced executive like Mr. Miller underscores Rigel’s ongoing commitment to strengthening its corporate governance framework and ensuring sound financial oversight as the company moves forward with its current marketed products and developmental pipeline assets. Investors and industry observers will likely view this appointment as a positive indicator of Rigel’s focus on sustainable growth and operational excellence.